

AMENDMENTS TO THE CLAIMS:

1-12. (canceled)

13. (previously presented) A pteridine derivative selected from the group consisting of:

- 2-amino-4-morpholino-6-(4-acetanilide) pteridine,
- 2-amino-4-morpholino-6-(3-acetanilide) pteridine,
- 2-amino-4-morpholino-6-(4-aminophenyl) pteridine,
- 2-amino-4-morpholino-6-(3-aminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-benzoylamino-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxyacetylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-propionylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-furoylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-cyclohexanoylamino-phenyl) pteridine,
- 2-amino-4-morpholino-6-[4-(4-chlorobenzoyl)aminophenyl] pteridine,
- 2-amino-4-morpholino-6-(4-benzyloxyacetylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-isonicotinoylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-(4-naphtoylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-(4-methylsulfonylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-(4-ethylsuccinylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-[4-(4-methylbenzoate)aminophenyl] pteridine;
- 2-amino-4-morpholino-6-(3-benzoylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-(3-benzensulfonylamino-phenyl) pteridine,
- 2-amino-4-morpholino-6-(3-phenoxyacetylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-isonicotinoylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-(3-cyclohexanoylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-[3-(4-methylbenzoate)aminophenyl] pteridine;
- 2-amino-4-morpholino-6-(3-ethylsuccinylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-(3-ethylmalonylamino-phenyl) pteridine;
- 2-amino-4-morpholino-6-(3-benzyloxyacetylaminophenyl) pteridine,

- 2-amino-4-morpholino-6-(3-ethylsulfonylamino-phenyl)pteridine,
- 2-amino-4-morpholino-6-[3-Boc-(L)-phenylalanine-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(D)-phenylalanine-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(L)-tryptophane-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(D)-tryptophane-aminophenyl] pteridine, and
- 2-amino-4-morpholino-6-(4-hydroxyphenyl) pteridine,
- 2,4-di-(thienyl-2-methylamino)-6-(3,4-dimethoxy-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-ethoxyphenyl) pteridine,
- 2-amino-4-morpholino-6-(4-benzyloxyphenyl) pteridine,
- 2-amino-4-morpholino-6-(4-(phenethyloxy)-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxy-butyronitrile) pteridine,
- 2-amino-4-morpholino-6-(4-propoxy-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxy-butyric acid ethyl ester) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxy-acetic acid ethyl ester) pteridine,
- 2-amino-4-morpholino-6-(4-(2-methoxyethoxy)-phenyl) pteridine,
- 2-amino-4-morpholino-6-(4-butoxy-phenyl)-pteridine,
- 2-amino-4-(diethanolamino)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-(benzylamino)-6-[[3,4-(dimethoxyphenyl)]pteridine;
- 2-amino-4-(phenylethylamino)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-(4-methyl-piperidine)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-(2-thienylmethylamino)-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-thiomorpholine-6-[[3,4-(dimethoxyphenyl)]pteridine,
- 2-amino-4-((*R*)-sec-butylamine)-6-[[3,4-(dimethoxyphenyl)]pteridine, and
- 2-amino-4-((*S*)-sec-butylamine)-6-[[3,4-(dimethoxyphenyl)]pteridine.

14. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13.

15. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13, and further comprising one or more biologically active drugs selected from the group consisting of immuno-suppressant and/or immunomodulator drugs.

16. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13, and further comprising one or more immunosuppressant drugs selected from the group consisting of cyclosporin A; pentoxifylline; daltroban, sirolimus, tacrolimus; rapamycin; leflunomide; mycophenolic acid and salts thereof; azathioprine, brequinar; gusperimus; 6-mercaptopurine; mizoribine; chloroquine; hydroxy-chloroquine; etanercept; infliximab; and kineret.

17. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13 and further comprising one or more immunomodulator drugs selected from the group consisting of acemannan, amiprilose, bucillamine, ditiocarb sodium, imiquimod, Inosine Pranobex, interferon- β , interferon- γ , lentinan, levamisole, pidotimod, romurtide, platonin, procodazole, propagermanium, thymomodulin, thymopentin and ubenimex.

18. (canceled)

19. (previously presented) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13 and further comprising one or more pharmaceutically acceptable carriers or excipients.

20 - 27. (canceled)